Innate Pharma (IPHA) announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma, or CTCL, treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology, or ASH, annual meeting in San Diego, California. The TELLOMAK study addresses an unmet need for patients with advanced-stage CTCL, particularly Sezary syndrome and mycosis fungoides, who often experience debilitating symptoms such as severe itching and recurrent skin infections that profoundly impact their physical and social well-being. Patients with relapsed or refractory CTCL face limited treatment options and often report lower health-related quality of life, particularly those in advanced stages. TELLOMAK’s findings reveal signs that lacutamab may help alleviate some of the most distressing symptoms of this disease early on treatment. The TELLOMAK trial enrolled 163 patients with advanced CTCL, including 56 with SS and 107 with MF. The study’s quality of life measures included the Visual Analogue Scale, or VAS, for itch intensity and the Skindex-29 score, a validated tool for assessing the impact of skin conditions on patient quality of life.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue